A series of reports released today by MTPConnect, an independent, industry-led organisation, highlight the key role the MedTech sector played in the COVID-19 pandemic response. The reports, welcomed by the Medical Technology Association of Australia (MTAA), reveal how the MedTech, biotechnology and pharmaceutical sector was impacted by COVID-19 at local and multinational levels, as well…

Read More

 Insights from Professor Stephen Clarke OAM This week, VIVA! Communications’ Principal, Kirsten Bruce spoke with award-winning Medical Oncologist, Pharmacologist and Translational Researcher, Professor Stephen Clarke OAM, Sydney, about clinical practice during COVID-19, the impact of the virus on cancer diagnosis and treatment, and how cancer patients are faring from a mental health perspective. Although the…

Read More

Yesterday, VIVA! partnered with Celgene, a Bristol-Myers Squibb company and Myeloma Australia to announce the listing of REVLIMID® (lenalidomide) in combination with bortezomib (Velcade) and dexamethasone (RVd) on the Pharmaceutical Benefits Scheme (PBS). Australians living with the incurable blood cancer, multiple myeloma now have access to this new treatment option. The three drug regimen will…

Read More

How to avoid faux pas & respect your fellow zoomies Working from home presents unique challenges and opportunities for those fortunate enough to be able to do so. Businesses and their employees are doing their best to navigate these unprecedented times, so it’s important to practice patience and respect. Here at VIVA! we are doing…

Read More